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We are now in a scientific era where advances in basic
understanding of cellular behaviour and technological break-
throughs are opening new and exciting avenues in cancer
research and clinical management of patients with malignant
disease. One such advancement is the development of mono-
clonal antibodies (Kohler & Milstein, 1975). Like many
other 'breakthroughs' in biomedical research, monoclonal
antibodies have been through the three phases of
maturation. At the beginning, there was the excitement and
hype that not only would monoclonal antibodies
revolutionise the diagnosis, but they would also cure many,
if not most, so far incurable cancers. In fact, early pilot
studies had suggested that this could be the case in both
diagnosis (Mach et al., 1981; Epenetos et al., 1982a; Farrands
et al., 1982) and therapy (Sears et al., 1982; Miller et al.,
1982). Unfortunately this euphoria was short lived because
subsequent and more comprehensive studies (Epenetos et al.,
1986) demonstrated a major fundamental problem with
antibody targeting. That was, that after intravenous
administration of monoclonal antibodies in patients, only a
very small proportion of the injectate localised to tumour
sites (-0.005% of the injected amount per gram of tumour)
which is approximately 100-1,000 times less than when the
same antibody is tested in animal models, e.g. nude mice
bearing human cancer xenografts (Epenetos et al., 1982b;
Schlom, 1986). These small amounts of antibodies are hardly
sufficient to allow successful imaging of small lesions
undiagnosed by existing conventional radiological techniques
and are certainly not sufficient to deliver tumoricidal
amounts of cytotoxic agents to tumour cells without
damaging other normal organs such as the bone marrow,
liver and kidneys.
So what is the state of the art with monoclonal antibodies
today? It is the author's opinion that we have now entered
the third and, it is hoped, final phase of maturity, which is
understanding the shortcomings of monoclonal antibodies
and designing methods to overcome them. To understand
the mechanism of antibody targeting to tumour tissues in
vivo, at least two aspects need to be considered.
The first is the host handling of the antibody, which
includes both normal and neoplastic tissues. After an
antibody is injected into the blood stream the following
events happen before it can reach the tumour cells (Jain,
1987): the antibody is diluted by the vascular volume;
transported across microvessel endothelial cells; enters
normal and neoplastic interstitium and binds on to specific
antigens and possible internalisation.
Data available so far (Jain, 1987) indicate that the
interstitial space of neoplastic tissues differs significantly
from that of normal tissues both in structure and function.
In general, tumours have high interstitial fluid pressure and
fluid flow, probably due to the fact that their interstitial
spaces are larger than normal and lack a functioning
lymphatic system. This may be an advantage in using
monoclonal antibodies for tumour targeting because a high
intratumoral interstitial fluid pressure and flow may allow
for more efficient interstitial diffusion of macromolecules
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such as antibodies. On the other hand, in large tumours high
interstitial pressure and low microvessel pressure may slow
down the extravasation of antibodies into tumour tissues. Of
course, before an antibody reaches the interstitium of
tumours it may be catabolised. Immunoglobulin catabolism
is carried out by the reticuloendothelial system and the liver
in particular, where both parenchymal and non-parenchymal
cells are involved (Sands et al., 1989).
The second aspect is the characteristics of individual
monoclonal antibodies and their conjugates. Monoclonal
antibodies, like all antibodies, consist of the minimum
essential part required to bind antigen, i.e. the antigen
binding loops of the V domains coded by the complemen-
tarity determining regions (CDRs) of the V genes and the
rest of the V domains as well as constant regions of heavy
and light immunoglobulin chains.
The exquisite specificity of monoclonal antibodies for their
targets is determined by the 3-D structure of the V domain
and CDR loops. The presence of tumour associated or
tumour 'specific' antigens is an essential prerequisite for
successful tumour targeting using antibodies. It is not the
purpose of this article to review human tumour antigens but,
rather, to focus on a few interesting examples which may
prove useful in our selection of antigen-antibody systems.
Human milk fat globule membrane
A highly immunogenic component of the human milk fat
globule membrane is a large molecular weight mucin
(>400kD) which is also secreted into milk (Ceriani et al.,
1982). A large number of tumour associated antigens defined
by existing monoclonal antibodies are carried out on mole-
cules that are immunologically related or identical to the
milk mucins (Taylor-Papadimitriou et al., 1981; Arklie et al.,
1981). Some tumour mucins are aberrantly or incompletely
glycosylated, allowing for their protein core to be exposed.
This observation has been exploited and new monoclonal
antibodies directed against protein core components of
tumour mucins have been produced (Burchell et al., 1987;
Gendler et al., 1987). Antibodies such as these, reacting with
protein determinants which are only exposed in tumours, can
be described as 'operationally tumour specific'.
In fact, from the vast pool of existing antitumour mono-
clonal antibodies, there exists a small group of antibodies
directed against unique epitopes of antigens that allow for
increased tumour specificity. These include the SM3
(Burchell et al., 1987; Gendler et al., 1987) against an
epitope of stripped mucin and found widely on carcinomas,
B72.3 (Hand et al., 1985) against a glycoprotein on many
tumours and OVTL3 (Poels et al., 1986) and MOV 18
(Miotti et al., 1987) against ovarian cancer.
Multiple drug resistance proteins
It is possible that the ultimate place of monoclonal anti-
bodies against cancer would be in conjunction with other
anticancer agents such as chemotherapy. In that case it
would be desirable and complementary if a monoclonal
antibody would target against chemotherapy-resistant cancer
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cells. Studies of multiple drug resistant mutant cells have
shed new light into drug transport in mammalian cells.
It would appear that simultaneous resistance to a wide
range of unrelated chemotherapy and other drugs is
mediated, at least in part, by an increase in a plasma
membrane glycoprotein (p-glycoprotein, 170kD) which acts
like a molecular pump exporting a variety of compounds,
including many chemotherapy drugs (Kartner et al., 1985).
Several monoclonal antibodies now exist that are directed
against p-glycoprotein (Sugawara et al., 1988). These may
prove useful in in vivo therapeutic applications.
Tumour microvasculature
Another interesting antigenic target for tumour therapy may
be the microvasculature of neoplastic tissues. If one could
target selectively and destroy the cells forming tumour
microvessels (without affecting, at the same time, normal
tissue microvessels) then a significant antitumour effect could
be achieved. In fact, recent reports (Watkins et al., 1989)
have indicated that some monoclonal antibodies originally
made against malignant gliomas may target specifically to
tumour microvessels.
Most clinical trials of in vivo diagnosis and therapy have
involved either mouse or rat monoclonal antibodies. A
crucial and yet not unexpected problem that has been
identified when using rodent antibodies in humans is the
sensitisation of the recipient to the administered xenogeneic
protein (Schroff et al., 1985; Courtenay-Luck et al., 1986).
Immunisation of patients would cause immune complex
disease and also abrogate any therapeutic effect due to rapid
clearance of administered antibody.
There are at least four ways that attempt to overcome this
problem. The first is to use existing rodent antibodies but to
delay and reduce the intensity of human antimouse antibody
responses by the use of immunosuppressive agents such as
cyclosporin A cyclophosphamide and steroids (Ortho
Multicenter Transport Study Group, 1985; Begent, 1989).
The second approach is to try and induce specific un-
responsiveness to rodent immunoglobulins by the use of
immunosuppressive antibodies (Benjamin & Waldmann,
1986) or by coupling substances such as polyethylene glycol,
which apparently may convert xenogeneic monoclonal anti-
bodies to specific tolerogens (Sehon, 1989). A third way is to
use human monoclonal antibodies produced from Epstein-
Barr virus transformed human b-lymphocytes or from
human or human mouse hybridomas (Sikora et al., 1982;
Cote et al., 1983). This approach has only had limited
success so far but a new technique exploiting the immuno-
logical idiotypic network (Ritter et al., 1987) may yield high
affinity and high specificity human monoclonal antibodies.
Finally, by using recombinant DNA technology it is now
possible to engineer antibodies where only the antigen
binding site is defined by mouse gene sequences and the rest
of the molecule is 'human' (Riechmann et al., 1988).
As stated earlier, the fundamental difficulty with antibody
targeting to tumours is the small amount of immunoglobulin
that reaches the tumour. Are there any ways to overcome
this problem? One possibility is to use smaller fragments of
the antibody molecule. It was thought that the large
molecular weight of the intact IgG might be responsible for
its poor accessibility to solid tumour tissue. It has been
shown, however, that the use of either monomeric (Fab) or
dimeric (Fab')2 fragments does not achieve higher amounts
of antibody in the tumour (Wahl et al., 1983). Fragments
produce faster and better tumour to non-tumour ratios
because they are cleared more rapidly from the circulation
and there is less non-specific uptake by Fc binding cells or
carbohydrate catabolising cells (Sands et al., 1989). A recent
development has been the recombinant production of Fv
fragments. These are the smallest possible intact fragments
of the antibody molecule that can bind antigen in the
appropriate configuration (Verhoeyen et al., 1988). Fv
fragments may prove superior in tumour targeting although
their small size (-25kD) may lead to even faster clearance.
A second possibility to increase tumour uptake of
antibody is to give a much higher amount of antibody as
long as this is relatively non-toxic to the host. It would be
advantageous if the cytotoxic moeity or imaging isotope
could then be delivered at a time when the tumour to non-
tumour ratios are optimal and at a time when there was no
significant circulating amount of antibody. Consideration of
the difficulties of delivering adequate quantities of antibody
has resulted in several current lines of research. Hybrid
antibodies with dual specificities can be produced by the cell
fusion of two Ig producing cell lines (Milstein & Guello,
1983; Clark & Waldmann, 1989) or by chemically
conjugating two monomeric Fab fragments (Perez et al.,
1985). Hybrid antibody may be capable of targeting
diagnostic or therapeutic radioisotopes such as indium-ill
and yttrium-90 (Goodwin, 1987) or targeting drug (Corvalan
et al., 1988) or toxins (Webb et al., 1985) to cells expressing
appropriate cell surface antigens. Of greater interest,
perhaps, may be the ability of these bispecific antibodies to
induce potent tumour cell killing by activated T-cells if the
bispecific antibody can cross-link T-cells and antigens on the
surface of tumour cells (Clark & Waldman, 1989; Clark et
al., 1988; Canevari et al., 1988).
Another novel approach is the in vivo use of streptavidin
conjugated antibodies followed, after an appropriate period
of time, by radioactive biotin either for imaging or therapy.
Biotin has an extremely high affinity for streptavidin
(Dd=15M-10) and at the same time is a small enough
molecule that can diffuse rapidly through most tissues in the
body. Using, initially, experimental models (Hnatowich et
al., 1987; Paganelli et al., 1988) and more recently clinical
studies (Hnatowich et al., 1989) it has been shown that the
tumour target to non-target ratios may be improved
considerably.
A different and rather interesting strategy has recently been
proposed by Professor K. Bagshawe and his colleagues, who
used a two-step approach (Bagshawe et al., 1989). In their
system a prodrug is activated at the tumour site by a non-
mammalian enzyme conjugated on to antibody. As the first
step, the antibody-enzyme conjugate is injected and allowed
to localise to tumours. After a certain period of time, it is
followed by a prodrug which diffuses readily through tissues.
This prodrug is relatively stable and only gets activated by
the targeted enzyme on tumour sites. The prodrug becomes a
highly toxic agent which can enter tumour cells and at the
same time has a short half-life so that it is of low toxicity to
normal tissues (Bagshawe et al., 1989).
We have already acknowledged the difficulties resulting
from the immunogenicity of rodent monoclonal antibodies
when injected repeatedly into humans. This problem may be
reduced but may not be totally eliminated even if one could
use human monoclonal antibodies because of the possibility
of developing anti-idiotypic and anti-allotypic antibodies
(Ritter et al., 1987). Can one, however, use this phenomenon
to the patient's advantage? It has been shown by several
workers (Schroff et al., 1985; Courtenay-Luck et al., 1986;
Ritter et al., 1987) that antigen antibody response developing
in recipients is partly directed against the variable region
(idiotype) of the administered antibody (anti-id1 response).
Some of these anti-idiotypic antibodies are directed against
the combining site (paratope) of the administered mono-
clonal antibody and therefore represent an 'internal image'
of the tumour antigen. In some cases, this can lead to a
marked elevation of human serum antibodies that themselves
bind to tumour antigen, with a specificity similar to that of
the injected antibody. These are now human anti-tumour
antibodies which may mediate a cytotoxic response. The
discovery of anti-idiotypic antibodies has led to the proposal
of making idiotypic vaccines in cases where purified tumour
antigen is not available or is presented to the immune system
in a non-immunogenic way. In fact animal studies using
tumour specific idiotypic vaccines have produced
encouraging results (Dunn et al., 1987; Raychaudhari et al.,
1987). Therefore, the effects of generating anti-idiotypic
responses may not necessarily be detrimental to the host. It154 A.A. EPENETOS & C. KOSMAS
may be possible to switch on such a response to the patient's
advantage once we know how to manipulate the idiotypic
network (Jerne, 1971) and provide the patient with auto-
anti-tumour antibodies.
Some new concepts such as new tumour targets,
recombinant antibodies and fragments, two-step strategies
and exploitation of the idiotypic network have been briefly
reviewed. In addition, there has been a great deal of progress
in the basic chemistry of immunoconjugates providing
increased stability and retention of immunoreactivity in
antibody-drug conjugates (Kanellos et al., 1985), immuno-
toxins (Thorpe et al., 1987), antibody-isotopes (Moi et al.,
1985; Gansow et al., 1989; Eaton et al., 1989; Abrams et al.,
1989) and site specific radiolabelling (Rodwell et al., 1986).
We are only at the beginning of fully evaluating the potency
of antibodies in cancer diagnosis and therapy. Some of the
main issues involved in this approach are discussed in the
proceedings of the Fifth International Meeting entitled
'Advances in the Application of Monoclonal Antibodies in
Clinical Oncology' and published in this issue of the British
Journal of Cancer.
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